Physician profile
Joseph R Sutherland
NPI 1841455326
$911.91
in general payments reported to CMS, 2019-2025
12 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.87 · 2022: $57.70 · 2024: $329 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $220.72 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $173.67 | 2024-2025 | Airsupra |
| Amgen INC. | $109.38 | 2024-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $91.89 | 2024-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $57.87 | 2021 | |
| Boston Scientific Corporation | $57.70 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.27 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $46.63 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $46.52 | 2024-2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $22.99 | 2025 | |
| Glaxosmithkline, LLC. | $19.14 | 2025 | Arexvy, Shingrix |
| Abbvie INC. | $16.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.